Immunome doses first patient in IM-1021 trial
Immunome (IMNM) announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC. Discover ...
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...